Genetic lessons learned from X-linked Mendelian susceptibility to mycobacterial diseases

Annals of the New York Academy of Sciences

Volumn 1246, Issue 1, 2011, Pages 92-101

  Bustamante, Jacinta ^a,b   Picard, Capucine ^a,b,c   Boisson Dupuis, Stéphanie ^a,b,d   Abel, Laurent ^a,b,d   Casanova, Jean Laurent ^a,b,c,d  

^a IMAGINE INSTITUTE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d ROCKEFELLER UNIVERSITY   (United States)

Author keywords

CYBB; Interferon ; Interleukin 12; Macrophages; Monocytes; Mycobacteria; NEMO; X linked primary immunodeficiency

Indexed keywords

BCG VACCINE; CD40 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN GP 91; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 23; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

AUTOSOME; BACTERIAL VIRULENCE; CELL LINEAGE; CELL TYPE; CHRONIC GRANULOMATOUS DISEASE; CYBB GENE; ECTODERMAL DYSPLASIA; GENE; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GERM LINE; HUMAN; INCONTINENTIA PIGMENTI; INFECTION SENSITIVITY; MACROPHAGE; MENDELIAN SUSCEPTIBILITY TO MYCOBACTERIAL DISEASE; MONONUCLEAR CELL; MYCOBACTERIOSIS; NEMO GENE; NONHUMAN; PHAGOCYTE; PHENOTYPE; RARE DISEASE; RESPIRATORY BURST; REVIEW; SIGNAL TRANSDUCTION; X CHROMOSOME LINKED DISORDER;

CORYNEBACTERINEAE; MYCOBACTERIUM BOVIS;

EID: 84855328689     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06273.x     Document Type: Review

References (100)

1. Hamosh, A. et al. 2005. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 33: D514-517.
2. Casanova, J.L. & L. Abel. 2002. Genetic dissection of immunity to mycobacteria: the human model. Annu. Rev. Immunol. 20: 581-620.
3. Filipe-Santos, O. et al. 2006. Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin. Immunol. 18: 347-361.
4. Alcais, A. et al. 2005. Tuberculosis in children and adults: two distinct genetic diseases. J. Exp. Med. 202: 1617-1621.
5. Boisson-Dupuis, S. et al. 2011. IL-12Rbeta1 deficiency in two of fifty children with severe tuberculosis from Iran, Morocco, and Turkey. PLoS One 6: e18524.
6. Tabarsi, P. et al. 2011. Lethal tuberculosis in a previously healthy adult with IL-12 receptor deficiency. J. Clin. Immunol. 31: 537-539.
7. Mimouni, J. 1951. Our experiences in three years of BCG vaccination at the center of the O.P.H.S. at Constantine; study of observed cases (25 cases of complications from BCG vaccination). Alger. Medicale 55: 1138-1147.
8. Casanova, J.L. et al. 1996. Idiopathic disseminated bacillus Calmette-Guerin infection: a French national retrospective study. Pediatric 98: 774-778.
9. Picard, C., J.L. Casanova & L. Abel. 2006. Mendelian traits that confer predisposition or resistance to specific infections in humans. Curr. Opin. Immunol. 18: 383-390.
10. Bustamante, J. et al. 2008. Novel primary immunodeficiencies revealed by the investigation of paediatric infectious diseases. Curr. Opin. Immunol. 20: 39-48.
11. Patel, S.Y. et al. 2008. Genetically determined susceptibility to mycobacterial infection. J. Clin. Patho. 61: 1006-1012.
12. Dorman, S.E. et al. 1999. Viral infections in interferon-gamma receptor deficiency. J. Pediatr. 135: 640-643.
13. Camcioglu, Y. et al. 2004. HHV-8-associated Kaposi sarcoma in a child with IFNgammaR1 deficiency. J. Pediatr. 144: 519-523.
14. Roesler, J. et al. 1999. Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-gamma-receptor (IFNgammaR1) deficiency: mutational analysis and evaluation of therapeutic options. Exp. Hematol 27: 1368-1374.
15. Pedraza, S. et al. 2010. Clinical disease caused by Klebsiella in 2 unrelated patients with interleukin 12 receptor beta1 deficiency. Pediatrics 126: e971-e976.
16. Picard, C. et al. 2002. Inherited interleukin-12 deficiency: iL12B genotype and clinical phenotype of 13 patients from six kindreds. Am. J. Hum. Genet. 70: 336-348.
17. Luangwedchakarn, V. et al. 2009. A novel mutation of the IL12RB1 gene in a child with nocardiosis, recurrent salmonellosis and neurofibromatosis type I: first case report from Thailand. Asian Pac. J. Allergy Immunol. 27: 161-165.
18. Zerbe, C.S. & S.M. Holland. 2005. Disseminated histoplasmosis in persons with interferon-gamma receptor 1 deficiency. Clin. Infect. Dis. 41: e38-e41.
19. Moraes-Vasconcelos, D. et al. 2005. Paracoccidioides brasiliensis disseminated disease in a patient with inherited deficiency in the beta1 subunit of the interleukin (IL)-12/IL-23 receptor. Clin. Infect. Dis. 41: e31-e37.
20. Vinh, D.C. et al. 2009. Refractory disseminated coccidioidomycosis and mycobacteriosis in interferon-gamma receptor 1 deficiency. Clin. Infect. Dis. 49: e62-e65.
21. Vinh, D.C. et al. 2011. Interleukin-12 receptor beta1 deficiency predisposing to disseminated coccidioidomycosis. Clin. Infect. Dis. 52: e99-e102.
22. Sanal, O. et al. 2007. A case of interleukin-12 receptor beta-1 deficiency with recurrent leishmaniasis. Pediatr. Infect. Dis. J. 26: 366-368.
23. Hambleton, S. et al. 2011. IRF8 mutations and human dendritic-cell immunodeficiency. N. Engl. J. Med. 365: 127-138.
24. Newport, M.J. et al. 1996. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335: 1941-1949.
25. Jouanguy, E. et al. 1996. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N. Engl. J. Med. 335: 1956-1961.
26. Jouanguy, E. et al. 1999. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat. Genet. 21: 370-378.
27. Jouanguy, E. et al. 2000. In a novel form of IFN-gamma receptor 1 deficiency, cell surface receptors fail to bind IFN-gamma. J. Clin. Invest. 105: 1429-1436.
28. Dorman, S.E. et al. 2004. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 364: 2113-2121.
29. Kong, X.F. et al. 2010. A novel form of cell type-specific partial IFN-gammaR1 deficiency caused by a germ line mutation of the IFNGR1 initiation codon. Hum. Mol. Genet. 19: 434-444.
30. Dorman, S.E. & S.M. Holland. 1998. Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection. J. Clin. Invest. 101: 2364-2369.
31. Doffinger, R. et al. 2000. Partial interferon-gamma receptor signaling chain deficiency in a patient with bacille Calmette-Guerin and mycobacterium abscessus infection. J. Infect. Dis. 181: 379-384.
32. Rosenzweig, S.D. et al. 2004. A novel mutation in IFN-gamma receptor 2 with dominant negative activity: biological consequences of homozygous and heterozygous states. J. Immunol. 173: 4000-4008.
33. Vogt, G. et al. 2005. Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nat. Genet. 37: 692-700.
34. Vogt, G. et al. 2008. Complementation of a pathogenic IFNGR2 misfolding mutation with modifiers of N-glycosylation. J. Exp. Med. 205: 1729-1737.
35. Dupuis, S. et al. 2001. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 293: 300-303.
36. Chapgier, A. et al. 2006. Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS. Genet. 2: e131.
37. Altare, F. et al. 1998. Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and salmonella enteritidis disseminated infection. J. Clin. Invest. 102: 2035-2040.
38. Fieschi, C. et al. 2003. Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: medical and immunological implications. J. Exp. Med. 197: 527-535.
39. Fieschi, C. et al. 2004. A novel form of complete IL-12/IL-23 receptor beta1 deficiency with cell surface-expressed nonfunctional receptors. Blood 104: 2095-2101.
40. de Beaucoudrey, L. et al. 2010. Revisiting human IL-12Rbeta1 deficiency: a survey of 141 patients from 30 countries. Medicine 89: 381-402.
41. Dupuis, S. et al. 2003. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat. Genet. 33: 388-391.
42. Chapgier, A. et al. 2006. Human complete STAT-1 deficiency is associated with defective type I and II IFN responses in vitro but immunity to some low virulence viruses in vivo. J. Immunol. 176: 5078-5083.
43. Kong, X.F. et al. 2010. A novel form of human STAT1 deficiency impairing early but not late responses to interferons. Blood 116: 5895-5906.
44. Chapgier, A. et al. 2009. A partial form of recessive STAT1 deficiency in humans. J. Clin. Invest. 119: 1502-1514.
45. Vairo, D. et al. 2011. Severe impairment of IFN{gamma} and IFN{alpha} responses in cells of a patient with a novel STAT1 splicing mutation. Blood 118: 1806-1817.
46. Jouanguy, E. et al. 2007. Human primary immunodeficiencies of type I interferons. Biochimie 89: 878-883.
47. Zhang, S.Y. et al. 2008. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol. Rev. 226: 29-40.
48. Frucht, D.M. & S.M. Holland. 1996. Defective monocyte costimulation for IFN-gamma production in familial disseminated mycobacterium avium complex infection: abnormal IL-12 regulation. J. Immunol. 157: 411-416.
49. Frucht, D.M. et al. 1999. IL-12-Independent costimulation pathways for interferon-gamma production in familial disseminated mycobacterium avium complex infection. Clin. Immunol. 91: 234-241.
50. Nedorost, S.T. et al. 1991. Rosacea-like lesions due to familial mycobacterium avium-intracellulare infection. Int. J. Dermatol. 30: 491-497.
51. Holland, S.M. et al. 1994. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N. Engl. J Med. 330: 1348-1355.
52. Filipe-Santos, O. et al. 2006. X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production. J. Exp. Med. 203: 1745-1759.
53. Zonana, J. et al. 2000. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am. J. Hum. Genet. 67: 1555-1562.
54. Jain, A. et al. 2001. Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat. Immunol. 2: 223-228.
55. Doffinger, R. et al. 2001. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat. Genet. 27: 277-285.
56. Priolo, M. & Lagana, C. 2001. Ectodermal dysplasias: a new clinical-genetic classification. J. Med. Genet. 38: 579-585.
57. Abinun, M. 1995. Ectodermal dysplasia and immunodeficiency. Arch. Dis. Child 73: 185.
58. Abinun, M. et al. 1996. Anhidrotic ectodermal dysplasia associated with specific antibody deficiency. Eur. J. Pediatr. 155: 146-147.
59. Carrol, E.D. et al. 2003. Anhidrotic ectodermal dysplasia and immunodeficiency: the role of NEMO. Arch. Dis. Child 88: 340-341.
60. Ku, C.L. et al. 2005. NEMO mutations in 2 unrelated boys with severe infections and conical teeth. Pediatrics 115: e615-e619.
61. Hubeau, M. et al. 2011. A new mechanism of X-linked anhidrotic ectodermal dysplasia with immunodeficiency: impairment of ubiquitin binding despite normal folding of NEMO protein. Blood 118: 926-935.
62. Puel, A. et al. 2006. The NEMO mutation creating the most-upstream premature stop codon is hypomorphic because of a reinitiation of translation. Am. J. Hum. Genet. 78: 691-701.
63. Orange, J.S. et al. 2004. Human nuclear factor kappa B essential modulator mutation can result in immunodeficiency without ectodermal dysplasia. J. Allergy Clin. Immunol. 114: 650-656.
64. Mooster, J.L. et al. 2010. Immune deficiency caused by impaired expression of nuclear factor-kappaB essential modifier (NEMO) because of a mutation in the 5' untranslated region of the NEMO gene. J. Allergy Clin. Immunol. 126: 127-132 e7.
65. Mansour, S. et al. 2001. Incontinentia pigmenti in a surviving male is accompanied by hypohidrotic ectodermal dysplasia and recurrent infection. Am. J. Med. Genet. 99: 172-177.
66. Dupuis-Girod, S. et al. 2002. Osteopetrosis, lymphedema, anhidrotic ectodermal dysplasia, and immunodeficiency in a boy and incontinentia pigmenti in his mother. Pediatrics 109: e97.
67. Smahi, A. et al. 2000. Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature 405: 466-472.
68. Smahi, A. et al. 2002. The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum. Mol. Genet. 11: 2371-2375.
69. Aradhya, S. et al. 2001. Atypical forms of incontinentia pigmenti in male individuals result from mutations of a cytosine tract in exon 10 of NEMO (IKK-gamma). Am. J. Hum. Genet. 68: 765-771.
70. Kosaki, K. et al. 2001. Female patient showing hypohidrotic ectodermal dysplasia and immunodeficiency (HED-ID). Am. J. Hum. Genet. 69: 664-666.
71. Nishikomori, R. et al. 2004. X-linked ectodermal dysplasia and immunodeficiency caused by reversion mosaicism of NEMO reveals a critical role for NEMO in human T-cell development and/or survival. Blood 103: 4565-4572.
72. Jain, A. et al. 2004. Specific NEMO mutations impair CD40-mediated c-Rel activation and B cell terminal differentiation. J. Clin. Invest. 114: 1593-1602.
73. Orstavik, K.H. et al. 2006. Novel splicing mutation in the NEMO (IKK-gamma) gene with severe immunodeficiency and heterogeneity of X-chromosome inactivation. Am. J. Med. Genet. A 140: 31-39.
74. Lee, W.I. et al. 2005. Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome. Blood 105: 1881-1890.
75. Ku, C.L. et al. 2007. IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease. J. Med. Genet. 44: 16-23.
76. Pachlopnik Schmid, J.M. et al. 2006. Transient hemophagocytosis with deficient cellular cytotoxicity, monoclonal immunoglobulin M gammopathy, increased T-cell numbers, and hypomorphic NEMO mutation. Pediatrics 117: e1049-e1056.
77. Tono, C. et al. 2007. Correction of immunodeficiency associated with NEMO mutation by umbilical cord blood transplantation using a reduced-intensity conditioning regimen. Bone Marrow Transplant 39: 801-804.
78. Hanson, E.P., L. Monaco-Shawver, L.A. Solt, et al. 2008. Hypomorphic nuclear factor-kappaB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity. J. Allergy Clin. Immunol. 122: e1169-e1177.
79. Salt, B.H., J.E. Niemela, R. Pandey, et al. 2008. IKBKG (nuclear factor-kappa B essential modulator) mutation can be associated with opportunistic infection without impairing Toll-like receptor function. J. Allergy Clin. Immunol. 121: 976-982.
80. Mancini, A.J., L.P. Lawley & G. Uzel. 2008. X-linked ectodermal dysplasia with immunodeficiency caused by NEMO mutation: early recognition and diagnosis. Arch. Dermatol. 144: 342-346.
81. Dupuis-Girod, S. et al. 2006. Successful allogeneic hemopoietic stem cell transplantation in a child who had anhidrotic ectodermal dysplasia with immunodeficiency. Pediatrics 118: e205-e211.
82. Roberts, C.M. et al. 2010. A novel NEMO gene mutation causing osteopetrosis, lymphoedema, hypohidrotic ectodermal dysplasia and immunodeficiency (OL-HED-ID). Eur. J. Pediatr. 169: 1403-1407.
83. Lo, Y.C. et al. 2009. Structural basis for recognition of diubiquitins by NEMO. Mol. Cell 33: 602-615.
84. Bustamante, J. et al. 2007. A novel X-linked recessive form of Mendelian susceptibility to mycobaterial disease. J. Med. Genet, 44: e65.
85. Bustamante, J. et al. 2011. Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat. Immunol. 12: 213-221.
86. Royer-Pokora, B. et al. 1986. Cloning the gene for an inherited human disorder-chronic granulomatous disease-on the basis of its chromosomal location. Nature 322: 32-38.
87. Dinauer, M.C. et al. 1987. The glycoprotein encoded by the X-linked chronic granulomatous disease locus is a component of the neutrophil cytochrome b complex. Nature 327: 717-720.
88. Teahan, C. et al. 1987. The X-linked chronic granulomatous disease gene codes for the beta-chain of cytochrome b-245. Nature 327: 720-721.
89. Roos, D., T.W. Kuijpers & J.T. Curnutte. 2007. Chronic granulomatous disease. In Primary Immunodeficiency Diseases. A Molecular and Genetic Approach. H.D. Ochs, C.I. Edvards Smith & J.M. Puch, Eds.: 525-549. Oxford University Press, New York.
90. Bustamante, J. et al. 2007. BCG-osis and tuberculosis in a child with chronic granulomatous disease. J. Allergy Clin. Immunol. 120: 32-38.
91. Lee, P.P. et al. 2008. Susceptibility to mycobacterial infections in children with X-linked chronic granulomatous disease: a review of 17 patients living in a region endemic for tuberculosis. Pediatr. Infect. Dis. J. 27: 224-230.
92. Holland, S.M. 2010. Chronic granulomatous disease. Clin. Rev. Allergy Immunol. 38: 3-10.
93. Roos, D. et al. 2010. Hematologically important mutations: x-linked chronic granulomatous disease (third update). Blood Cells Mol. Dis. 45: 246-265.
94. Conley, M.E., et al. 2009. Primary B cell immunodeficiencies: comparisons and contrasts. Annu. Rev. Immunol. 27: 199-227.
95. Boztug, K. & C. Klein. 2009. Novel genetic etiologies of severe congenital neutropenia. Curr. Opin. Immunol. 21: 472-480.
96. Segal, A.W. 2005. How neutrophils kill microbes. Annu. Rev. Immunol. 23: 197-223.
97. Casanova, J.L. & L. Abel. 2007. Primary immunodeficiencies: a field in its infancy. Science 317: 617-619.
98. Alcais, A., L. Abel & J.L. Casanova. 2009. Human genetics of infectious diseases: between proof of principle and paradigm. J. Clin. Invest. 119: 2506-2514.
99. Notarangelo, L.D. & J.L. Casanova. 2009. Primary immunodeficiencies: increasing market share. Curr. Opin. Immunol. 21: 461-465.
100. Alcais, A. et al. 2011. Life-threatening infectious diseases of childhood: single-gene inborn errors of immunity? Ann. N.Y. Acad. Sci. 1214: 18-33.